No-Spa (Drotaverine Hydrochloride)

Drotaverine Hydrochloride, the active ingredient in No-Spa, is a phosphodiesterase inhibitor (antispasmodic) presented as an injectable solution for intramuscular and intravenous use. It relaxes smooth muscle fibers and is employed to alleviate abdominal, biliary, renal and uterine cramping in adult patients. GNH USA supplies No-Spa as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Drotaverine acts on smooth‑muscle spasm disorders across the gastrointestinal, biliary, renal and reproductive systems. - Abdominal and gastrointestinal spasm: Relieves pain by relaxing intestinal smooth muscle. - Biliary colic: Reduces gall‑bladder wall tension, easing biliary pain. - Renal colic: Facilitates ureteral smooth‑muscle relaxation to lessen kidney‑stone discomfort. - Dysmenorrhea: Decreases uterine muscle contractions, improving menstrual pain. - Uterine cramping: Alleviates postpartum or procedural uterine spasms.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Nausea: Mild to moderate stomach upset. - Dizziness: Transient light‑headedness, especially after rapid administration. - Flushing: Warm sensation and reddening of the skin. - Headache: Tension‑type headache occurring shortly after dosing. - Hypotension: Mild drop in blood pressure, usually asymptomatic. - Dry mouth: Reduced salivation during treatment.

Serious or Rare Side Effects: - Allergic reaction: Rash, itching, or angioedema requiring medical attention. - Severe hypotension: Marked blood‑pressure fall with dizziness or syncope. - Cardiac arrhythmia: Irregular heartbeat reported in isolated cases. - Anaphylaxis: Rapid onset of systemic allergic response, a medical emergency. - Blood dyscrasias: Rare reports of leukopenia or thrombocytopenia.

Before initiating therapy, consider patient‑specific factors and monitor for adverse events. - Pregnancy: Use only if clearly needed, as safety data are limited. - Breastfeeding: Caution advised; limited information on excretion in milk. - Hepatic or renal impairment: Dose adjustment may be required; monitor organ function. - Concomitant antihypertensives: Observe blood pressure for additive hypotensive effect. - Known hypersensitivity: Avoid in patients with documented drotaverine allergy. - Store at 2-8°C: Keep refrigerated, protect from light, do not freeze.

Drotaverine may modify the effect of other medicines; interaction severity varies.

Major Interactions (Avoid): - Combined use with other potent antispasmodics: Increases risk of profound smooth‑muscle relaxation and hypotension. - Co‑administration with strong antihypertensive agents: May cause excessive blood‑pressure reduction.

Moderate Interactions (Monitor Closely): - NSAIDs: May mask pain, complicating clinical assessment. - Diuretics: Potentially augment hypotensive response. - Beta‑blockers: May require closer blood‑pressure monitoring.